Frequent EpCam protein expression in human carcinomas.

Expression of the transmembrane glycoprotein EpCam (epithelial cellular adhesion molecule) occurs in normal epithelium of different organs and was described in carcinomas of various sites. Specific anti-EpCam therapies are now being used in clinical trials. Thus, it is of interest to know which tumor types express or overexpress this protein, and in what frequency. We therefore analyzed EpCam expression by immunohistochemistry on a tissue microarray containing 3900 tissue samples of 134 different histological tumor types and subtypes. EpCam expression was detected in 98 of 131 tumor categories. At least a weak EpCam expression in >10% of tumors was observed in 87 of 131 different tumor categories. Adenocarcinomas of the colon (81%) and pancreas (78%), as well as hormone-refractory adenocarcinomas of the prostate (71%), were identified as particularly promising therapy targets with a high fraction of strongly positive tumors. Most soft-tissue tumors and all lymphomas were EpCam negative. It is concluded that anti-EpCam therapies, if proven to be successful, will have broad applications in a wide variety of carcinomas.

[1]  K. Huebner,et al.  Retroposition in a family of carcinoma-associated antigen genes , 1993, Molecular and cellular biology.

[2]  H. Moch,et al.  Tissue microarray (TMA) technology: miniaturized pathology archives for high‐throughput in situ studies , 2001, The Journal of pathology.

[3]  P. Went,et al.  Edrecolomab in the adjuvant treatment of colorectal carcinoma , 2003, The Lancet.

[4]  P. Möller,et al.  Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. , 1987, Cancer research.

[5]  D. Sansonno,et al.  Expression and distribution of a human colon-carcinoma-associated antigen in normal and diseased liver tissue. , 1993, Pathobiology : journal of immunopathology, molecular and cellular biology.

[6]  M. Omary,et al.  Multifocal heterogeneity in villin and Ep‐CAM expression in Barrett's esophagus , 1996, International journal of cancer.

[7]  K. Klein,et al.  Patterns of antigen distribution in human carcinomas. , 1990, Cancer research.

[8]  J. V. van Krieken,et al.  Expression of Ep‐CAM in normal, regenerating, metaplastic, and neoplastic liver , 1999, The Journal of pathology.

[9]  S. Szala,et al.  Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Bostwick,et al.  Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. , 1999, The Journal of urology.

[11]  M. Borowitz,et al.  Characterization of the human tumor and normal tissue reactivity of the KS1/4 monoclonal antibody. , 1988, Hybridoma.

[12]  C. Cordon-Cardo,et al.  Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[14]  E. Schuuring,et al.  Markers for assessment of nodal metastasis in laryngeal carcinoma. , 1997, Archives of otolaryngology--head & neck surgery.

[15]  D. Edwards,et al.  Cancer 43 , 000 Membrane Glycoprotein Associated with Human Breast r M Monoclonal Antibody Identification and Characterization of a Updated Version , 2006 .

[16]  J. Packeisen,et al.  Detection of surface antigen 17-1A in breast and colorectal cancer. , 1999, Hybridoma.

[17]  P. Ruck,et al.  Ep‐CAM in malignant liver tumours , 2000, The Journal of pathology.

[18]  L. Schwartzberg.  Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. , 2001, Critical reviews in oncology/hematology.

[19]  A. Henry,et al.  Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  P. Kufer,et al.  In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment , 2002, International journal of cancer.

[21]  C. Punt,et al.  Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study , 2002, The Lancet.

[22]  S. Litvinov,et al.  The biology of the 17–1A antigen (Ep-CAM) , 1999, Journal of Molecular Medicine.

[23]  R. Reisfeld,et al.  Antigens associated with a human lung adenocarcinoma defined by monoclonal antibodies. , 1984, Cancer research.

[24]  G. Riethmüller,et al.  The epithelial cell surface antigen 17–1A, a target for antibody‐mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodies , 1986, International journal of cancer.

[25]  O. Kallioniemi,et al.  Tissue microarrays (TMAs) for high‐throughput molecular pathology research , 2001, International journal of cancer.

[26]  P. Quirke,et al.  Expression of the 17-1A antigen in gastric and gastro-oesophageal junction adenocarcinomas: a potential immunotherapeutic target? , 1999, Journal of clinical pathology.

[27]  M. Herlyn,et al.  Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[28]  G. Mikuz,et al.  Prognostic significance of Ep‐CAM AND Her‐2/neu overexpression in invasive breast cancer , 2002, International journal of cancer.

[29]  J. Izbicki,et al.  Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  K. Pienta,et al.  E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. , 2001, Human pathology.

[31]  C. Cordon-Cardo,et al.  Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group‐related antigens , 1997, International journal of cancer.

[32]  J. Witte,et al.  Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  S. Braun,et al.  Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  Holger Moch,et al.  Tissue Microarrays: What Will They Bring to Molecular and Anatomic Pathology? , 2001, Advances in anatomic pathology.

[35]  E. Schuuring,et al.  Expression of genetic markers in lymph node metastases compared with their primary tumours in head and neck cancer , 2001, The Journal of pathology.

[36]  D. Heimburger,et al.  The expression of Ep-CAM (17-1A) in squamous cell cancers of the lung. , 2000, Human pathology.

[37]  V. Reuter,et al.  Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.